Druggability assessments identified <i>HDAC9</i> as a target for approved drugs potentially repurposed for VC, while PheWAS results suggested a predicted lack of severe genetic pleiotropy for most candidates, with the notable exception of <i>CDKN2A</i>, which showed associations with neoplasms. This evidence concerns the gene CDKN2A and neoplasm.